15th Mar 2021 17:07
(Alliance News) - The European Medicines Agency said it would hold an "extraordinary meeting' on Thursday on the AstraZeneca PLC vaccine after key countries suspended its use over blood clot fears, adding that the benefits of using the jab still outweighed the risks.
The EMA said in a statement that it would "further review the information" on the jab Tuesday, and had "called an extraordinary meeting on Thursday.... to conclude on the information gathered and any further actions that may need to be taken."
source: AFP
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca